ADC Therapeutics S.A. (NYSE:ADCT) Q2 2025 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to the ADC Therapeutics SA ADCT Q2 2025 Earnings Conference Call.
Adc Therapeutics Sa (ADCT)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Redmile Group Jeremy Green | 15,666,731 | $41,986,839 | 4.47% | |
| 2. | Prosight Capital Lawrence Hawkins | 10,467,771 | $28,053,626 | +10% | 6.84% |
| 3. | Point72 Asset Management Steve Cohen | 7,763,658 | $20,806,603 | 0.04% | |
| 4. | OrbiMed Advisors Samuel Isaly | 5,907,351 | $15,831,701 | -2% | 0.4% |
| 5. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 2,266,289 | $6,073,655 | 0.24% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.81 | 50,000 | $190,500.00 | 13,145,712 | 2024-12-11 | Filing | |
| $2.28 | 50,000 | $114,000.00 | 13,095,712 | 2024-12-11 | Filing | |
| $3.81 | 50,000 | $190,500.00 | 15,666,731 | 2024-12-11 | Filing | |
| $2.28 | 50,000 | $114,000.00 | 15,616,731 | 2024-12-11 | Filing | |
| $2.81 | 400,000 | $1,124,000.00 | 12,995,040 | 2024-07-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.07 | 25,352 | $52,478.64 | 15,566,731 | 2024-12-04 | Filing | |
| $2.89 | 6,995 | $20,215.55 | 53,005 | 2024-06-17 | Filing | |
| $2.89 | 6,995 | $20,215.55 | 79,502 | 2024-06-17 | Filing | |
| $2.89 | 1,193 | $3,447.77 | 182,644 | 2024-06-17 | Filing | |
| $2.89 | 1,437 | $4,152.93 | 106,627 | 2024-06-17 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,521,343 | $12,117,199 | 0% | |
| 2. | 3,045,573 | $8,162,136 | 0% | |
| 3. | 2,832,861 | $7,592,067 | 2.03% | |
| 4. | 2,199,059 | $5,893,478 | 0% | |
| 5. | 1,542,602 | $4,134,173 | 0% |
News See All
ADC Therapeutics SA (NYSE:ADCT) Q1 2025 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to ADC Therapeutics' First Quarter 2025 Earnings Call.
ADC Therapeutics SA (NYSE:ADCT) Q4 2024 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to the ADC Therapeutics Fourth Quarter Fiscal Year 2024 Earnings Conference Call. At this time, all lines are in listen-only mode.
ADC Therapeutics SA (NYSE:ADCT) Q3 2024 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to the ADC Therapeutics Third Quarter 2024 Earnings Conference Call.
ADC Therapeutics SA (NYSE:ADCT) Q2 2024 Earnings Call Transcript
Operator: Welcome to the ADC Therapeutics Second Quarter 2024 Financial Results Conference Call. My name is Didi, and I will be your operator for today's call.
ADC Therapeutics SA (NYSE:ADCT) Q1 2024 Earnings Call Transcript
ADC Therapeutics SA reports earnings inline with expectations. Reported EPS is $-0.56 EPS, expectations were $-0.56.
ADC Therapeutics SA (NYSE:ADCT) Q4 2023 Earnings Call Transcript
ADC Therapeutics SA misses on earnings expectations. Reported EPS is $-1.03 EPS, expectations were $-0.47.
5 Top Performing European Stocks So Far in 2024
In this piece, we will take a look at the five top performing European stocks so far in 2024.
ADC Therapeutics SA (NYSE:ADCT) Q3 2023 Earnings Call Transcript
Operator: Welcome to the ADC Therapeutics Third Quarter 2023 Financial Results Conference Call. My name is Cathy and I will be your operator for today's call.
ADC Therapeutics SA (NYSE:ADCT) Q2 2023 Earnings Call Transcript
Operator: Hello, and welcome to the ADC Therapeutics Second Quarter 2023 Financial Results Conference Call. My name is Corey, and I'll be your operator for today's call.